Abclon Q1 2026: Positive AT101 CAR-T Phase 2 Data and AC101 Global Phase 3 Progress

Q1 2026 revenue: 434M KRW (+5.2% YoY), net loss 2.78B KRW (improved from 5.98B loss in Q1 2025)
Cash and equivalents: 36.11B KRW; short-term financial products 6B; total assets 68.43B; debt ratio 17.4% – stable financial position
AT101 (Nespe-cel) CAR-T: Phase 2 interim results show ORR 94%, CR 68%, superior to existing CAR-T; designated as development-stage orphan drug and Global Innovative products on Fast Track (GIFT)
AC101 (HLX22): Global Phase 3 for HER2+ gastric cancer ongoing; first patient dosed in Phase 2/3 combo trial with HER2 ADC 'HLX87' in March 2026; INN (dulpatatug) approved; FDA and EC orphan drug designations
AT101 tech transfer: Exclusive rights to TCT Health Technology (Turkey) signed Feb 2025
R&D expenses: 2.19B KRW (504% of sales); key pipelines progressing: AT101, AC101, AM105, AM109, AT501
No material contingencies or litigation

ADVERTISEMENT (250px+)